ArticleOncology letters2020

miR-429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/β-catenin signaling pathway.

Liangzhi Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.